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Scale-down models are often used for the definition of operating ranges in process development and validation 
and therefore data exploitation is an important task. Usually, the experimental scientists have very tight timelines 
and consequentially may often only perform the required routine of cleaning and sorting the data without more 
sophisticated analyses, even though it might improve data quality. This problem is more exacerbated by the rise 
of fully automated, miniaturized high-throughput equipment in up- and downstream process development where 
data processing automation is not just optional but a must. However, cleaned, sorted and time-aligned data 
alone do not guarantee a sufficient representation of the process. Often, further data enrichment to extract 
relevant process parameters is required but omitted due to time constraints. The benefit of data enrichment is 
true process understanding [1]: the calculation of scalable rates and yields, minima, maxima, median or 
derivatives of measured online or offline signals and the categorization into clone, lot, feeding strategy, seed 
train fitness, feed or media can be easily used to explain variation in the current process. Multivariate regression 
methods such as partial least squares regression (PLS-R) or hybrid models [2] can then be used to explain the 
contribution and ranking of critical process parameters (CPPs) such as pH, pO2, temperature, metabolite 
concentrations or metabolic rates towards particular critical quality attributes (CQAs), for instance glycoform 
distribution, other product quality attributes or cell growth. The knowledge of these parameters can then feed 
directly into the generation of a statistically verified design space which may be then used for process scale-up 
and validation [3,4]. Summarizing this contribution, we present a methodology to automate data enrichment. Our 
suggested data enrichment concept is exemplified shown on upstream micro bioreactor data and comprise one 
of the necessary steps to characterize and ultimately qualify scale-down process models. 
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